BioMarin Pharmaceutical Sees FY23 EPS $0.78-$1.03 Vs $0.95 Est.; FY23 $2.375M-$2.5M Vs $2.46B Est.

Item

2023 Guidance

Updated April 26, 2023

Total Revenues

$2,375

to

$2,500

Unchanged

Enzyme Product Revenues(1)

$1,700

to

$1,850

Unchanged

ROCTAVIAN Revenues

$100

to

$200

$50

to

$150

VOXZOGO Revenues

$330

to

$380

$380

to

$430

Unchanged

Gross Profit %

77.5 %

to

79 %

Unchanged

R&D % of Revenue

30 %

to

32 %

Unchanged

SG&A % of Revenue

36 %

to

38 %

Unchanged

GAAP Net Income

$155

to

$205

Unchanged

GAAP Diluted EPS

$0.78

to

$1.03

Unchanged

Non-GAAP Income

$360

to

$410

Unchanged

Non-GAAP Diluted EPS

$1.80

to

$2.05

Unchanged